Respiratory Medicine
Volume 104, Issue 4 , Pages 606-611, April 2010

Adenosine for vasoreactivity testing in pulmonary hypertension: A head-to-head comparison with inhaled nitric oxide

Cardiology Service, Hospital das Clínicas and Internal Medicine Department, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 190 – Campus Saúde – 30130-100, Belo Horizonte, MG, Brazil

Received 28 July 2009; accepted 17 November 2009. published online 04 December 2009.

Summary 

Background

APVT is an invasive method recommended for symptomatic patients with PAH that permits the identification of the minority of patients (<20%) that may benefit from long-term calcium channel blockers. Adenosine has been indicated in guidelines as a vasodilator agent of choice for APVT, although it has not been directly compared with iNO, the gold standard for this test. The objective of the study was to compare adenosine with inhaled nitric oxide (iNO) for acute pulmonary vasoreactivity testing (APVT) in pulmonary arterial hypertension (PAH), in order to determine the efficacy and safety of the first in the clinical setting.

Methods

The measurements of cardiac output, pulmonary and systemic resistance were done in the basal state and with a stepwise increase of the dose of each drug until either maximum dosage (adenosine: 500 μg/kg/min or iNO: 80 ppm) or side effects observed or a positive response were reached, according to current guidelines. The order of drugs used in each test was consecutively alternated during the study.

Results

Six of the 39 studied patients (15%) presented a positive response to iNO; none to adenosine (p = 0.047, McNemar's test). Twenty-three patients (59%) did not reach the maximum dose of adenosine due to side effects, including bronchospasm, thoracic pain and bradycardia.

Conclusions

APVT testing with adenosine was not able to detect PAH patients responsive to iNo and provoked frequent adverse effects. Adenosine should not be used as a vasodilator drug in APVT.

Keywords: Pulmonary hypertension, Adenosine, Diagnosis, Nitric oxide

Abbreviations: APVT, Acute pulmonary vasoreactivity testing, CCB, Calcium channel blocker, CHD, Congenital heart disease, CO, Cardiac output, iNO, Inhaled nitric oxide, PA, Pulmonary artery, PAH, Pulmonary arterial hypertension, PCWP, Pulmonary capillary wedged pressure, PVR, Pulmonary vascular resistance, WHO, World Health Organization

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial support: AL Ribeiro is supported by the Brazilian research agencies CNPq – Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasília, Brazil, and FAPEMIG – Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Belo Horizonte, Brazil. These research agencies had no influence in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PII: S0954-6111(09)00374-6

doi:10.1016/j.rmed.2009.11.010

Respiratory Medicine
Volume 104, Issue 4 , Pages 606-611, April 2010